Skip to main content
Signal8
Launch Terminal
Dutia Suren G profile photo

Suren G. Dutia

CIK: 0001514063

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

CITIUS ONCOLOGY, INC. logo
CTOR

CITIUS ONCOLOGY, INC.

Director
Citius Pharmaceuticals, Inc. logo
CTXR

Citius Pharmaceuticals, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (3 total)

  • CITIUS ONCOLOGY, INC. logo
    CTOR

    CITIUS ONCOLOGY, INC.

    Sep 19, 2025
    Award(A)
    Direct
    300K shares-
  • CITIUS ONCOLOGY, INC. logo
    CTOR

    CITIUS ONCOLOGY, INC.

    Dec 12, 2024
    Award(A)

    Stock Option (Right to Buy)

    Direct
    125K shares-
  • Citius Pharmaceuticals, Inc. logo
    CTXR

    Citius Pharmaceuticals, Inc.

    Nov 7, 2024
    Award(A)

    Stock Option (Right to Purchase Common Stock)

    Direct
    125K shares-

1-3 of 3

About Dutia Suren G

Dutia Suren G (SEC CIK 0001514063) files insider reports with the SEC as Director of CITIUS ONCOLOGY, INC. (CTOR) and Director of Citius Pharmaceuticals, Inc. (CTXR).

Signal8 holds 5 ownership filings by Dutia Suren G, all Form 4s, filed between Nov 12, 2024 and Dec 22, 2025. Those filings report 3 transactions, from Nov 7, 2024 to Sep 19, 2025. Signal8's Form 4 history starts in Sep 2024.

The business address on Dutia Suren G's filings is in CRANFORD, NJ.

Recent filings by Dutia Suren G

  • Sep 19, 2025: Grant or award of CTOR shares (Form 4, code A).
  • Dec 12, 2024: Grant or award of CTOR derivative securities (Form 4, code A).
  • Nov 7, 2024: Grant or award of CTXR derivative securities (Form 4, code A).

Other insiders filing for CITIUS ONCOLOGY, INC. (CTOR)

How to read Form 4 transaction codes